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Summary Special techniques such as serial macroscopic sectioning (SMS) or immunohistochemical staining
(IH) improve the detection rate of micrometastases but this detection is of value only if it improves the
prediction of recurrence and survival.
We first studied the prognosis of 120 patients with a single micrometastasis detected by SMS in a series of
1,680 primary operable breast carcinoma with a median follow-up of 7 years. A significant difference in
recurrence (P = 0.005) and in survival (P = 0.0369) was found between node-negative patients and those with
one single SMS micrometastasis, but SMS micrometastases were not a predicting factor by multivariate
analyses according to the Cox model.
We then studied the prognostic significance of patients with a micrometastasis detected by IH in node-
negative carcinoma: 37 micrometastases from a series of 89 invasive lobular carcinoma (ILC) and 13 single
micrometastases from a series of 129 invasive ductal carcinoma (IDC). In the ILC group, IH micrometastases
had no prognostic value (median follow-up: 9.3 years). In the IDC group, IH micrometastases were correlated
with recurrences (P = 0.01) and were the most significant predicting factor, but were less correlated with
survival (median follow-up: 15.6 years).
Three main points emerge from this study:
(1) SMS micrometastases have a prognostic significance and macroscopic sectioning is recommended as a
routine technique not requiring excessive work.
(2) IH micrometastases in infiltrating lobular carcinoma have no prognostic significance.
(3) The value of IH is debatable in infiltrating ductal carcinoma, since the technique is of principal use in
predicting recurrences. It should therefore be carefully assessed vs other prognostic factors currently under
study.
Metastases to axillary lymph nodes is an important factor in
predicting prognosis in primary operable carcinoma of the
breast. Although it is now accepted that special techniques
such as serial sectioning or immunohistochemical stainings
allow an increased rate of detection of axillary node micro-
metastases, the prognostic significance of such detected
metastases is differently assessed according to techniques and
teams.
In this study we develop our former results (de Mascarel et
al., 1982; Trojani et al., 1987a and b) on the prognostic
significance of these micrometastases: on the one hand,
micrometastases detected by serial macroscopic sectioning
(SMS micrometastases) with a larger sample and a longer
follow-up; on the other hand, micrometastases detected by
immunohistochemical stainings (IH micrometastases) in
node-negative carcinoma with similar samples and a longer
follow-up. IH micrometastases were previously found to have
a prognostic significance in invasive ductal carcinoma (Tro-
jani et al., 1987a) but not in invasive lobular carcinoma
(Trojani et al., 1987b).
Prognostic value of micrometastases detected by serial macro-
scopic sectioning (SMS micrometastases)
Materials and methods
We studied 1,121 patients: 785 node-negative and 336 with
only one invaded node among a series of 1,680 consecutive
patients operated for primary invasive carcinoma (IC) of the
breast between 1980 and 1986. A Patey type mastectomy
with axillary node dissection was performed in 776 (70%);
118 patients received complementary radiotherapy and 188
chemotherapy; 345 (30%) underwent tumorectomy with axil-
lary node dissection and radiotherapy, and 118 received
chemotherapy. The mean age of the patients was 56 years at
operation with a range from 23 to 85 years.
Histologic tumour types were classified according to the
WHO 1981 classification and graded according to SCARFF
and BLOOM. Distribution of tumour size, pathologic criteria
and hormonal status are presented in Table I. The majority
of these tumours were Ti, T2 and corresponded to invasive
ductal carcinoma (NOS). More than half were positive for
one or two hormonal receptors.
Serial macroscopic sectioning
Since 1980 we have examined axillary lymph nodes by serial
macroscopic sectioning. The axillary contents are fist fixed
for 24 h in Bouin's solution and oriented. Afterwards, nodes
are isolated and numbered. Each node is entirely cut into
1.5 mm thick slices. According to its volume each node is cut
into 1 to 15 slices (mean 2.7) and examined in its entirety
(except when macroscopic examination can be focused on an
obvious metastatic slice). These slices are placed together in
as many numbered cassettes as necessary (Graph 1). The
number of cassettes required to submit each node in its
entirety ranges from 1 (90% of the cases) to three. Small
emboli of tumour cells in the sinus margin and/or metastatic
deposits in the lymph node parenchyma which are less than
0.5 mm in diameter are named micrometastases; macrometas-
tases are defined as metastatic parenchymal deposits greater
than 0.5 mm in diameter. The mean number of lymph nodes
in each case was 15 with a range from 2 to 39. Single micro-
metastases were detected in 120 cases (7% of the primary
operable carcinoma of the breast) and single macrometa-
stases in 216 cases (13%). There was an equal distribution
between emboli (53 cases) and parenchymal micrometastases
(59 cases), and association of both (eight cases). There was
no correlation between nodal metastatic size and histologic
tumour type or tumour grade.
The median follow-up was 82.6 months with a range from
33 to 136. There were 54 patients who developed contra-
lateral breast carcinoma and 18 of these presented recur-
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Table I Distribution oftumour size, pathologic criteria and hormonal
status in 1121 N- and IN+ patients
Criteria Number ofpatients
Tumour size TO
TI
T2
T3
Histologic type IDCa
IDC-IDa
ILCa
Others
76
312
652
81
834
119
107
61
Lymphatic invasion Present 248
Absent 703
Not specified 170
Grade I 242
II 402
III 286
Not specifiedb 191
Hormonal receptors Positive 625
ER, PRC
Negative 203
Not done 293
22
63
15
21.5
36
25.5
17
(both: 415)
(one: 210)
7
28
58
7
74
11
10
5
56
18
26
aIDC = invasive ductal carcinoma; IDC-ID = invasive ductal car-
cinoma with predominant intraductal component; ILC = invasive
lobular carcinoma. bInvasive component is too minimal to be graded in
84 IDC-ID; no grading in 107 ILC. CER, PR = Estrogen and Pro-
gesterone receptors.
1 node
A significant difference in recurrence (P= 0.005) and in sur-
vival (P = 0.0369) was found between node-negative patients
and those with one single micrometastasis whatever its type
(Figure 1). This difference was more obvious between node-
negative patients and those with one single macrometastasis
(P = 0.0001 for both recurrence and survival). In our study,
there was no significant prognostic difference between
patients with a single micrometastasis and patients with a
single macrometastasis.
Multivariate analyses according to the Cox model were
performed with several factors: age, tumour size, grade, lym-
phatic invasion, presence of micrometastasis or macrometas-
tasis, hormonal receptors and chemotherapy. The most
significant factors for recurrence were lymphatic invasion
(P= 7 x 10-6), grade (P= 8 x 10-5), tumour size (P=
0.0007) and the presence of one macrometastasis (P= 0.03).
For survival, the most significant factors were grade (P=
9 x 10-6), tumour size (P= 0.00015), negative progesterone
receptor (P= 0.0018) and lymphatic invasion (P = 0.016).
Micrometastases and the other factors were not significant.
Discussion
Serial sectioning can be performed either on one paraffin-
embedded block which is serially sectioned at x microns at x
levels according to teams (Fisher et al., 1978; Huvos et al.,
1971; LBCSG, 1990; Pickren, 1961), or on a fixed node
which is entirely cut into 1 to 1.5 mm slices (de Mascarel,
1
0.9
m 0.8
c
' 0.7
0 0.6
c 0.5
0
r- 0.4
0
0
QL 0.2
0.1
1 block = 1 slide
Graph 1 Serial macroscopic technique.
2H
- fb9-91
0 1 2 3 4 5 6 7
Years post surgery
8 9 10 11
1
0.9
0.8
rences. The total number of recurrences was 229 (20.1%):
183 distant metastases ± locoregional recurrences, 46 loco-
regional recurrences without distant metastases. The majority
of these recurrences (187 cases) fell into a 1-5 year period.
There was no correlation between recurrence type and lymph
node invasion. The number of patients who died from their
cancer was 130 (11.5%).
Statistical analysis
The clinical course was studied by two variables; recurrence
rate and survival including only patients who died from the
cancer. The method of Kaplan and Meier was used in cal-
culating recurrence and survival curves. The logrank test was
used to examine the statistical significance of differences
observed. The difference between two curves was considered
to be statistically significant if P for the logrank test was
<0.05. Lastly, multivariate analyses were performed accord-
ing to a Cox model to predict recurrences of clinical and
pathologic criteria. We used 1L and 2L programs from
BMDP software.
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Figure 1 Serial macroscopic sectioning metastases and survival:
785 node-negative patients (N-), 120 patients with one micro-
metastasis (m), and 216 patients with one macrometastasis (M).
a, Disease-free survival (n = 229 patients): N- ( , n = 129)
recur less than m ( , n = 32), P= 0.005, or M (---,
n = 68), P = 0.0001). b, Breast carcinoma survival = deaths due
to ipsilateral breast carcinoma (n = 130 patients): N- ( 9
n = 72) have better survival than m ( , n = 18) P = 0.04, or
M (- --, n=40), P=0.0001.
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1982; Friedman, 1988). The first sectioning technique can be
called serial microscopic sectioning and is used by different
teams to detect occult metastases and their prognostic signi-
ficance in standard node-negative breast carcinoma. The
second technique can be called serial macroscopic sectioning
and is used as a prospective routine technique. We have
compared our results to those in the literature according to
the techniques used. Thus, by serial microscopic sectioning,
Pickren (1961), Huvos et al. (1971) and Fisher et al. (1978)
failed to find any significant difference in survival between
patients whose nodal metastases were occult and those in
whom they were absent. On the other hand, the Ludwig
group (LBCSG, 1990; LBCSG, 1988; Munro-Neville, 1990)
found that there was a definite outcome disadvantage for the
83 patients (9%) who converted to the node-positive classi-
fication in 5-year disease-free survival and in overall survival,
but no prognostic difference was found between micro- and
macrometastases.
By serial macroscopic sectioning Friedman (1988) found
that the presence of a clandestine metastasis (small emboli of
tumour cells in the sinus margin) in one axillary node pro-
duced an increased risk of distant relapse compared to the
group with no identified metastases in the axillary lymph
node. This risk was identical to that of the group with one
parenchymal metastasis and to other combinations of from
one to three axillary node metastases. In addition, although
the group with only one clandestine metastasis received no
locoregional irradiation in contrast to the one parenchymal
metastasis and more advanced groups, the rate of local
relapse was not significantly increased.
By routine procedures Rosen found an identical prognosis
at 10 years for TINIMO patients with a single micro- or
macrometastasis, but a poorer one than in negative lymph
node patients. On the other hand, for T2NlMO patients, no
significant differences were found at 5 or 10 years by compar-
ing the curves for negative lymph node and single micro-
metastases (Rosen et al., 1989; Rosen et al., 1981; Rosen et
al., 1981). Prognostic significant of single metastasis size was
also found by Huvos et al. (1971) and Wilkinson et al.
(1981).
Thus, despite the different techniques the prognostic influ-
ence of micrometastases has been found by several teams;
however, their significance has been variously appreciated vs
macrometastasis.
Prognostic value of micrometastases detected by immunohis-
tochemical stainings in standard node-negative carcinoma (IH
micrometastases)
Materials and methods
A first series (Trojani et al., 1987a) concerned 129 con-
secutive N-MO patients with invasive non-lobular carcinoma
between 1965 and 1977, and a second series consisted of 89
N-MO patients with invasive lobular carcinoma between 1965
and 1987 (Trojani et al., 1987b). All these patients were
treated by Patey type mastectomy and axillary node dissec-
tion. In the invasive ductal carcinoma group (IDC) 27
patients (21%) were post-operatively irradiated and eight
(6%) received a brief course of radiotherapy. In the invasive
lobular carcinoma group (ILC) 13 cases (15%) underwent a
radiation therapy. All slides of tumours and lymph nodes
had been reviewed.
Distribution of tumour size and pathologic criteria in the
129 N-MO IDC patients is shown in Table II. In the 89
N-MO ILC patients, tumour size was distributed as follows:
TO, 3; TI, 24; T2, 51; T3, 4; Tx, 7. At that time hormonal
status was not specified for most of the cases. The mean age
of the patients was 57 years at operation (range 30-80 years)
in the IDC group and 58 years (range 35-80 years) in the
ILC group. The mean number of lymph nodes examined in
each case was 13 (range 5-29) in the IDC group and 14
(range 2-29) in the ILC group. The slides used were original
Table II Distribution oftumour size and pathologiccriteria in 129 N-
MO IDC patients
Number ofpatients Percentage
Tumour size TO 3 2
TI 65 50
T2 43 33
T3 5 8
T3 3 4
Tx 3
Histologic type IDC 112 87
IDC-ID 6 5
Others 11 8
Grade I 24 19
II 59 46
III 42 32
SAIa 4 3
Lymphatic invasion Present 103 80
Absent 24 19
Not specified 2 1
aInvasive component is too minimal to be graded in 2 IDC-ID.
H&E sections stained by a three-stage immunoperoxidase
procedure with a cocktail of five monoclonal antibodies
directed against epithelial cell antigens, according to a
previously described technique (Trojani et al., 1987a).
IH micrometastases were more frequent in ILC: 37 cases
(41%) than in IDC: 13 cases (10%). In the IDC group there
was always a single micrometastasis; in the ILC group micro-
metastases were detected either in one (26%), two (6%),
three (6%) or four (3%) lymph nodes. IH micrometastases
were composed of single cells in ILC and of small cell
clusters in IDC. No relationship was found between the
presence of these occult micrometastases and pathologic
criteria or treatment.
The median follow-up was 15.6 years for the IDC group
(most patients fell into a 10-20 year period), and 9.3 years
for the ILC group (most in a 5-15 year period).
In the IDC group, the total number of recurrences was 22
(17%): 19 distant metastases ± locoregional recurrences and
three locoregional recurrences without distant metastases.
Most of these recurrences (14 cases) fell into a 1-6 year
period. There were 11 patients who developed a contralateral
breast cancer. Two of these presented recurrences and had to
be excluded from the final analysis owing to the impossibility
of determining the breast responsible. The number of
patients who died from their cancer was 18 (14%).
In the ILC group, the total number of recurrences was 15;
13 distant metastases ± locoregional recurrences and two
locoregional recurrences without distant metastases. Most of
these recurrences (ten cases) fell into a 1-5 year period.
There were 11 patients who developed a contralateral breast.
Four of these presented recurrences and had to be excluded
from the final analysis owing to the impossibility of deter-
mining the breast responsible. The number of patients who
died from their cancer was eight (9%). Statistical analysis
was carried out as previously described.
Results
In the IDC group a significant difference in recurrence
(P = 0.01) was found between IH node-negative patients and
those with one single IH micrometastasis (Figure 2). The
correlation was not significant for survival (P = 0.07). Multi-
variate analyses according to the Cox model were performed
with several factors in the IDC group: age, tumour size,
grade, mitoses, differentiation and lymphatic invasion. For
recurrences the presence of micrometastases was the most
significant factor (P = 0.011) followed by mitotic index (P =
0.04) and age (P = 0.04). For survival, the presence of micro-
metastases was also significant (P = 0.027), but less so than
mitotic index (P = 0.006) and age (P = 0.011).
In the ILC group no correlation was found between the
presence of micrometastases and recurrence or survival rate.526 I. DE MASCAREL et al.
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Figure 2 Immunohistochemical metastases and survival in the
invasive ductal carcinoma group = 114 node-negative patients (N-),
13 patients with one micrometastasis (m). Disease-free survival
(n= 20): N- ( , n = 15) recur less than m ,n = 5),
P=0.01.
Discussion
It is not accepted that immunohistochemical stainings in-
crease the rate of detection of micrometastases whatever the
histologic type and whatever the methodology used [original
HES sections (Byrne et al., 1987; Trojani et al., 1987a,b) or
further microscopic sectioning (Bussolati et al., 1986; Caval-
lere et al., 1989; Noel et al., 1989; Sedmak et al., 1989).
However, the significance of such detected micrometastases
still remains a much debated question. Only a few teams
have studied the prognostic significance of IH micrometas-
tases (Bussolati et al., 1986; Byrne et al., 1987; Galea et al.,
1990; Sedmak et al., 1989; Trojani et al., 1987a,b). Bussolati
et al. (Byrne et al., 1987) studied a series of 50 cases of
infiltrating lobular carcinoma and found 24% of micrometas-
tases. Despite an insufficient follow-up (3-5 years: range 2 to
7 years), they failed to find any correlation between positive
cases and recurrence or survival rates. Byrne et al. (1987) and
Galea et al. (1990) did not find any significance of such
detected IH micrometastases (respectively four IH micro-
metastases in 40 N- breast carcinoma with 5 years follow-up
and nine IH micrometastases in 98 N- breast carcinoma with
13 years follow-up). On the other hand, Sedmak et al. (1989)
in 45 N- breast carcinoma with minimum 10 years follow-up
found that the survival curve for patients with IH detected
metastases (11%) was significantly worse than that of
patients without IH detected metastases (P = 0.0197). Histo-
logic type was not specified in these series.
The present study strengthens our former results in the
ILC group in which IH micrometastases had no prognostic
value. In the IDC group, IH micrometastases were still cor-
related with recurrences and were the most significant pre-
dicting factor, but were less important for predicting survival.
Conclusion
In conclusion, SMS micrometastases do have a prognostic
significance. However, serial macroscopic sectioning does not
require excessive work and we continue with it at our insti-
tution. On the other hand, it is now well established that IH
micrometastases have no prognostic value in infiltrating lobu-
lar carcinoma and are of minor interest in the IDC group
since they are mainly useful in predicting recurrences. These
results are especially important since more cumbersome tech-
niques cannot be used as a routine procedure in many
laboratories.
Since the demonstration of axillary lymph node micro-
metastases has a limited value in predicting survival, the
study of new biologic factors in primary tumours must be
developed. Several such factors are potential candidates:
oncogene products, different kinds of enzymes, hormonal
receptor-linked proteins and proliferative index.
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